Janux Therapeutics (JANX) Competitor Comparison
We are evaluating the key criteria listed to compare Janux Therapeutics (JANX) against its competitors in the Biotechnology industry.
Market Capitalization
73 / 368Gross Profits
191 / 278Total Revenue
188 / 300EBITDA
169 / 337Free Cashflow
170 / 352Quick Ratio
26 / 357Earnings per Share
146 / 359Dividend yield
0 / 6Total Cash
105 / 358Performance 3 years
30 / 368Performance 5 years
100 / 368Performance 10 years
80 / 368Linearity 3 years
347 / 368Linearity 5 years
336 / 368Linearity 10 years
328 / 368Total Rank
169 / 368Dividend Rank
173 / 368Valuation Rank
48 / 368Piotroski Rank
206 / 368Muliplier Rank
129 / 368EBITDA - JANX ranking 169 / 337
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.